WO2004039388A1 - α−グルコシダーゼ阻害剤 - Google Patents
α−グルコシダーゼ阻害剤 Download PDFInfo
- Publication number
- WO2004039388A1 WO2004039388A1 PCT/JP2003/013872 JP0313872W WO2004039388A1 WO 2004039388 A1 WO2004039388 A1 WO 2004039388A1 JP 0313872 W JP0313872 W JP 0313872W WO 2004039388 A1 WO2004039388 A1 WO 2004039388A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- obesity
- family
- plant
- ameliorating
- Prior art date
Links
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 title abstract 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 19
- 241000196324 Embryophyta Species 0.000 claims abstract description 14
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 241000209504 Poaceae Species 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 241000255601 Drosophila melanogaster Species 0.000 claims description 4
- 241000208422 Rhododendron Species 0.000 claims description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000019109 Patrinia villosa Nutrition 0.000 abstract description 8
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 241000606264 Patrinia Species 0.000 abstract 2
- 241000792902 Valerianaceae Species 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 244000148137 Patrinia villosa Species 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 240000009088 Fragaria x ananassa Species 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000219193 Brassicaceae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000009267 Patrinia scabiosaefolia Nutrition 0.000 description 2
- 244000011358 Patrinia scabiosaefolia Species 0.000 description 2
- 240000008488 Thlaspi arvense Species 0.000 description 2
- 235000008214 Thlaspi arvense Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000020083 shōchū Nutrition 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001049176 Charis Species 0.000 description 1
- 241000383250 Dendropanax trifidus Species 0.000 description 1
- 241000078604 Diplophyllum albicans Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 241000255990 Helicoverpa Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- -1 dissolution aids Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an ⁇ -darcosidase inhibitor that is safe and effective even when taken for a long period of time.
- Hi-Darcosidase is an enzyme that catalyzes the breakdown of carbohydrates in the digestive tract. When its function is inhibited, the degradation of carbohydrates is suppressed or delayed, and the absorption of carbohydrates can be suppressed. Therefore, an ⁇ -dalcosidase inhibitor remarkably suppresses postprandial hyperglycemia, and is therefore effective in preventing or improving diabetes, obesity, and the like.
- ⁇ -darcosidase inhibitors such as acarbose and voglipose are used as diabetic agents for the treatment of diabetes. These drugs were reported to be less severe but unpleasant to the patient, such as increased intestinal gas, and better drugs were sought.
- ⁇ -darcosidase inhibitors derived from natural products include ⁇ -g, which is obtained by extracting Mao ⁇ from water, a polar solvent or a mixed solvent thereof.
- Lucosidase inhibitor Japanese Patent Application Laid-Open No. 9-12963
- a dalcosidase inhibitor containing an extract of allspice and filiform as an active ingredient Japanese Patent Publication 2001--18
- Tengcha Shimabarai strawberry, “Remoco”
- Gosho strawberry Toku strawberry
- Mouth strawberry The carbohydrate digestion enzyme inhibitor containing elladinnin obtained from Henryi bowl as an active ingredient No.
- An object of the present invention is to provide an ⁇ -dalcosidase inhibitor that is safe and effective even when taken continuously for a long period of time.
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, it has been found that certain crude drugs have an excellent inhibitory activity against mono-dalcosidase, and that a glucose tolerance or an increase in blood glucose at the time of diabetes. They found that they are useful as pharmaceuticals and foods by suppressing them, and completed the present invention.
- a high-glucosidase inhibitor that contains high grasses derived from a plant of the family Ominae.
- An agent for preventing or ameliorating diabetes which contains high grasses derived from a plant of the family Ominae.
- An agent for preventing or ameliorating obesity which contains high grasses derived from a plant of the family Ominae.
- a dalcosidase inhibitor containing scotch bacterium which is based on otokosh or ominaesi.
- a preventive or ameliorating agent for obesity which contains high shosou based on otokosh or ominaesi.
- Rhododendron spp. Based on a plant of the family Poaceae for the manufacture of a prophylactic or therapeutic agent for diabetes or obesity.
- the ginseng used in the present invention is based on a plant belonging to the family Ominae It is used in the form of herbal powder, extracts extracted with water, polar solvents, mixed solvents thereof, etc., dried extracts, and stream extracts.
- the efficacy of crude drugs may vary depending on their origins. preferable.
- the dose of the ⁇ -dalcosidase inhibitor of the present invention can be appropriately increased or decreased in consideration of age, gender, etc., but is usually in the range of 100 mg to 50 g as a crude drug equivalent per day for an adult. It can be used and preferably ranges from 500 mg to 30 g.
- the present invention provides vitamins, xanthine derivatives, amino acids, excipients, pH adjusters, fresheners, suspending agents, defoamers, and viscous agents within a qualitative and quantitative range that does not impair the effects of the present invention.
- Oral or parenteral preparations such as solutions, tablets, granules, powders, capsules, dry syrups, chewable tablets, and transmucosal preparations can be made.
- FIG. 1 is a graph showing the ⁇ -darcosidase activity inhibition rate of a high-potassium extract based on the protocol of the present invention, in which the vertical axis represents the inhibition rate and the horizontal axis represents the concentration.
- FIG. 2 is a diagram showing the inhibition rate of mono-dalsosidase activity for each of the extracts of Drosophila aeruginosa having different base materials, wherein the ordinate represents the inhibition rate and the abscissa represents the concentration.
- FIG. 3 shows the extract of ⁇
- FIG. 3 is a graph showing the effect on blood glucose elevation during sucrose loading, in which the vertical axis represents blood glucose level, and the horizontal axis represents crude drug name and dosage.
- FIG. 4 shows the dose-dependency of the effect of sucrose on blood glucose elevation.
- the vertical axis shows the blood glucose level and the horizontal axis shows the dose.
- FIG. 5 is a graph showing the effect of the high-salt extract on ob / ob mice in diabetes, wherein the ordinate represents the blood glucose level, and the abscissa represents the name and dosage of the crude drug.
- Example 1 Using the extract of Drosophila melanogaster obtained in Example 1 (dissolved in 2.5% DMSO) and the extract derived from D. albicans obtained in Comparative Example 1, the inhibitory effect on human dalcosidase was measured by the method shown in Test Example 1. . Each herbal extract was added at a final concentration of 1.556, 3.13, 6.25, 12.5 and 25 g / mL.
- a crude drug extract was orally administered to an SD male rat (6 weeks old, Nippon Charis River) at a dose of 300 mg / kg (dry extract equivalent), and 5 minutes later, a sucrose solution was added at 2 g / kg. It was administered orally at a dose of kg. Water was orally administered to the normal group (no sucrose administration) and the control group.
- Oral administration was performed at a dose of 150, 300, 600 mg / kg (in dry extract), and measurement for suppression of blood glucose elevation after administration of sucrose was performed by the method described in Test Example 3. Was.
- Ob / ob mice (mice expressing hyperglycemia) were administered at a dose of 300 mg / kg (dry dry equivalent) per day with the extract of Drosophila melanogaster based on the otokosh obtained in Example 1. Oral administration for 8 weeks. The patient was fasted from 5:00 in the evening on the last day of administration, and blood was collected from the posterior vena cava the next day under ether anesthesia. Get The serum was separated from the collected blood by a centrifugation method (3000 rpm, 20 ° C), and the glucose concentration in the serum was quantified according to the method described in Test Example 3.
- the present invention is effective in inhibiting carbohydrate absorption based on the inhibitory action of mono-dalcosidase and in improving postprandial hyperglycemia, and is therefore effective in preventing or improving obesity and diabetes.
- the present invention it is possible to prevent or improve an increase in blood sugar level due to excessive intake of carbohydrate, and to provide a highly safe drug or food capable of preventing or improving lifestyle-related diseases such as obesity and diabetes. Became.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004548075A JPWO2004039388A1 (ja) | 2002-10-30 | 2003-10-29 | α−グルコシダーゼ阻害剤 |
AU2003280609A AU2003280609A1 (en) | 2002-10-30 | 2003-10-29 | Alpha-GLUCOSIDASE INHIBITOR |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-316152 | 2002-10-30 | ||
JP2002316152 | 2002-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004039388A1 true WO2004039388A1 (ja) | 2004-05-13 |
Family
ID=32211673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013872 WO2004039388A1 (ja) | 2002-10-30 | 2003-10-29 | α−グルコシダーゼ阻害剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2004039388A1 (ja) |
AU (1) | AU2003280609A1 (ja) |
WO (1) | WO2004039388A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004250445A (ja) * | 2003-01-31 | 2004-09-09 | Yakult Honsha Co Ltd | グリケーション阻害剤及びその利用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5690011A (en) * | 1979-12-25 | 1981-07-21 | Tsumura Juntendo Inc | Cholagogue |
-
2003
- 2003-10-29 AU AU2003280609A patent/AU2003280609A1/en not_active Abandoned
- 2003-10-29 WO PCT/JP2003/013872 patent/WO2004039388A1/ja active Application Filing
- 2003-10-29 JP JP2004548075A patent/JPWO2004039388A1/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5690011A (en) * | 1979-12-25 | 1981-07-21 | Tsumura Juntendo Inc | Cholagogue |
Non-Patent Citations (5)
Title |
---|
IIO MASAYOSHI ET AL.: "Effect of flavonoids on alpha-glucosidase and beta-fructosidase from yeast", AGRIC. BIOL. CHEM., vol. 84, no. 6, 1984, pages 1559 - 1563, XP002964800 * |
INADA AKIRA ET AL.: "Phytochemical studies of seeds of medicinal plants IV flavonids and triterpenoids from patrinia villosa (THUNB.)", JUSS, SHOYAKUGAKU ZASSHI, vol. 47, no. 3, 1993, pages 301 - 304, XP002964798 * |
KIM SUNG HEE ET AL.: "Inhibitation of carbo hydrate-digesting enzymes and amelioration of glucose tolerance by Korean medicinal herbs", J. FOOD SCIENCE AND NUTRITION, vol. 7, no. 1, 2002, pages 62 - 66, XP002964797 * |
NAKAMURA SEIJI ET AL.: "Flavonoid glycoside alpha-glucosoidase inhibitors, from leaves of zozyphus jujuba mill. var. inermis Rehd", NATURAL MEDICINES, vol. 52, no. 4, 1998, pages 372, XP002964799 * |
WATANABE JUNE ET AL.: "Isolation and identification of alpha-glucosidase inhibitors from tochucha (Eucommia ulmoides)", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 61, no. 1, 1997, pages 177 - 178, XP009030015 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004250445A (ja) * | 2003-01-31 | 2004-09-09 | Yakult Honsha Co Ltd | グリケーション阻害剤及びその利用 |
Also Published As
Publication number | Publication date |
---|---|
AU2003280609A1 (en) | 2004-05-25 |
JPWO2004039388A1 (ja) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7976880B2 (en) | Pregnane glycoside compositions and Caralluma extract products and uses thereof | |
EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
WO2006116410A2 (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
JP2004105157A (ja) | 糖類分解酵素阻害飲食組成物 | |
KR100828069B1 (ko) | 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물 | |
JP2012006975A (ja) | リパーゼ阻害剤 | |
JP2007520431A (ja) | 血糖降下用組成物 | |
KR20100040270A (ko) | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도 | |
KR100891881B1 (ko) | 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 mmp 과다활성으로 인한 혈관질환 예방 및치료용 조성물 | |
KR102310813B1 (ko) | 숙잠 및 효모 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
JP4706174B2 (ja) | α−グルコシダーゼ阻害剤 | |
WO2004039388A1 (ja) | α−グルコシダーゼ阻害剤 | |
JP4547892B2 (ja) | α−グルコシダーゼ阻害剤 | |
JP2000342228A (ja) | ヤーコン・桑葉配合茶 | |
JP2009007328A (ja) | 抗アレルギー性組成物 | |
RU2780346C1 (ru) | Терапевтический агент против коронавируса, включающий экстракт elaeocarpus sylvestris | |
TWI766295B (zh) | 一種草本組合物及其降尿酸、降低體脂肪及降低血糖之用途 | |
US20070028930A1 (en) | Active agent and formulations to minimize or alleviate bladder urgency and irritation and/or to enhance sexual function | |
KR20120055159A (ko) | 감국 추출물을 포함하는 불면 증상의 예방 및 개선용 조성물과 그의 제조방법 | |
KR102507928B1 (ko) | 괭생이모자반 추출물을 유효성분으로 함유하는 비용종 질환 예방 또는 치료용 조성물 | |
JP2003226650A (ja) | 医薬用組成物 | |
KR100773246B1 (ko) | 연령초 추출물을 유효성분으로 함유하는 비만 억제 및 혈당강하용 조성물 | |
JP2009275026A (ja) | 膵臓リパーゼ活性阻害作用を有する組成物 | |
JP4604506B2 (ja) | α−グルコシダーゼ阻害剤 | |
JP2004168767A (ja) | α−グルコシダーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004548075 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |